Results 291 to 300 of about 406,491 (336)
Overcoming Chemotherapy Resistance in Triple-Negative Breast Cancer with Nanocarrier-Delivered siRNA Therapeutics. [PDF]
J Clin MedCrintea A +7 more
europepmc +1 more source
Pathogenesis of Triple-Negative Breast Cancer
Annual Review of Pathology: Mechanisms of Disease, 2022 Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of fundamentally different diseases with different histologic, genomic, and immunologic profiles, which are aggregated under this term because of their lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression.
Fatemeh Derakhshan, Jorge S Reis-Filho
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Opinion in Oncology, 2008
Triple-negative breast cancer has been of great interest to oncologists because these cancers do not benefit from hormonal therapies or treatments targeted against human epidermal growth factor receptor 2 receptors. The only systemic therapy currently available is chemotherapy, and prognosis remains poor.
Gert, Stockmans +4 more
semanticscholar +6 more sources
Triple-negative breast cancer has been of great interest to oncologists because these cancers do not benefit from hormonal therapies or treatments targeted against human epidermal growth factor receptor 2 receptors. The only systemic therapy currently available is chemotherapy, and prognosis remains poor.
Gert, Stockmans +4 more
semanticscholar +6 more sources
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
New England Journal of Medicine, 2021 Copyright © 2021 Massachusetts Medical Society. BACKGROUND Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the human trophoblast cell ...
Aditya Bardia +2 more
exaly +2 more sources
Pembrolizumab for Early Triple-Negative Breast Cancer
New England Journal of Medicine, 2020 BACKGROUND Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer.
Javier Cortes +2 more
exaly +2 more sources
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
New England Journal of Medicine, 2022 BACKGROUND The addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and ...
Javier Cortes +2 more
exaly +2 more sources
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
New England Journal of Medicine, 2022 BACKGROUND In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed ...
Javier Cortes
exaly +2 more sources
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Nature Reviews Clinical Oncology, 2016 Giampaolo Bianchini +2 more
exaly +2 more sources
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
New England Journal of Medicine, 2018 Background Unresectable locally advanced or metastatic triple‐negative (hormone‐receptor–negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is an aggressive disease with poor outcomes.
Hope S Rugo +2 more
exaly +2 more sources